RNAZ

+ Watchlist + Portfolio

TransCode Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.21
52-Week Range: $2.87 – $20.99
Market Cap: $3.14M
P/E (TTM): —
EPS (TTM): -41.82
Dividend Yield: —

Advanced Metrics

Price/Book: 2.18
PEG Ratio: —
Return on Equity: -59.28%
Return on Assets: -19.90%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.97
Debt/Equity: 0.00
Total Debt: $652.41K
Free Cash Flow: $-13.49M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $208.61M

RNAZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.23M	$12.26M	$9.71M	$13.42M
Selling, General & Admin	$8.40M	$7.15M	$5.95M	$5.77M
Operating Expenses	$17.55M	$18.50M	$15.14M	$17.92M
Operating Income	-$17.55M	-$18.50M	-$15.14M	-$17.92M
EBITDA	-$17.43M	-$17.97M	-$16.19M	-$34.31M
Pretax Income	-$17.56M	-$18.55M	-$16.75M	-$34.44M
Income Tax	—	—	$0.00	$226.07K
Net Income	-$17.56M	-$18.55M	-$16.75M	-$34.66M
Diluted EPS	-1033233.41	-27313.84	-1336.63	-52.59
Diluted Shares	17	679	12558	689713

RNAZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.97M	$2.77M	$5.81M	$17.81M
Receivables	$360.23K	$0.00	$0.00	$953.10K
Current Assets	$7.38M	$4.46M	$7.09M	$21.98M
Total Assets	$7.59M	$5.17M	$7.29M	$162.40M
Current Liabilities	$4.35M	$3.49M	$2.77M	$3.49M
Total Debt	$0.00	$450.57K	$38.29K	$0.00
Total Liabilities	$4.35M	$3.53M	$9.31M	$10.52M
Retained Earnings	-$27.87M	-$46.42M	-$63.20M	-$97.86M
Shareholders' Equity	$3.24M	$1.64M	-$2.02M	$151.88M
Working Capital	$3.03M	$964.85K	$4.32M	$18.49M

RNAZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.76M	-$18.07M	-$13.34M	-$19.52M
Capital Expenditure	-$100.92K	-$35.61K	-$21.76K	-$6.66K
Free Cash Flow	-$15.86M	-$18.11M	-$13.36M	-$19.52M
Depreciation & Amortisation	$98.61K	$516.75K	$534.86K	$114.18K
Stock-Based Compensation	$395.33K	$1.04M	$1.70M	$485.43K
Investing Cash Flow	-$100.92K	-$35.61K	-$21.76K	-$4.44K
Financing Cash Flow	$5.99K	$15.91M	$16.40M	$31.52M
Net Change in Cash	-$15.86M	-$2.20M	$3.04M	$12.00M

RNAZ Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.22M	$2.57M	$3.16M	$5.48M	$15.53M
Selling, General & Admin	$951.65K	$1.66M	$1.40M	$1.76M	$2.22M
Operating Expenses	$2.82M	$4.07M	$4.54M	$6.49M	$17.62M
Operating Income	-$2.82M	-$4.07M	-$4.54M	-$6.49M	-$17.62M
EBITDA	-$12.03M	-$4.26M	-$4.85M	-$13.17M	-$17.53M
Pretax Income	-$12.09M	-$4.28M	-$4.86M	-$13.22M	-$17.55M
Income Tax	$0.00	—	—	—	$231.31K
Net Income	-$12.09M	-$4.28M	-$4.86M	-$13.44M	-$17.79M
Diluted EPS	-70.16	-5.13	-5.82	—	-21.28
Diluted Shares	172262	833654	834373	—	916968

RNAZ Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$11.57M	$7.37M	$2.84M	$17.81M	$12.84M
Receivables	$322.44K	$176.12K	$198.30K	$953.10K	$638.00
Current Assets	$13.04M	$8.24M	$4.75M	$21.98M	$16.75M
Total Assets	$13.19M	$8.27M	$5.23M	$162.40M	$157.16M
Current Liabilities	$2.51M	$1.56M	$2.97M	$3.49M	$5.38M
Total Debt	$0.00	$0.00	$0.00	$0.00	—
Total Liabilities	$2.90M	$2.12M	$3.80M	$10.52M	$12.64M
Retained Earnings	-$75.29M	-$79.56M	-$84.42M	-$97.86M	-$115.65M
Shareholders' Equity	$10.29M	$6.15M	$1.43M	$151.88M	$144.52M
Working Capital	$10.53M	$6.68M	$1.78M	$18.49M	$11.37M

RNAZ Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.10M	-$4.19M	-$4.08M	-$8.14M	-$4.98M
Free Cash Flow	-$3.10M	-$4.19M	-$4.08M	-$8.15M	-$4.98M
Depreciation & Amortisation	$51.17K	$13.44K	$4.78K	$44.78K	$23.94K
Stock-Based Compensation	$157.73K	$131.51K	$134.32K	$61.87K	$0.00
Investing Cash Flow	$0.00	$0.00	$0.00	-$4.44K	—
Financing Cash Flow	$8.85M	$0.00	-$455.73K	$23.12M	$0.00
Net Change in Cash	$5.76M	-$4.19M	-$4.54M	$14.98M	-$4.98M

Market Snapshot

About

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on developing RNA therapeutics for cancer treatment. The company utilizes its proprietary TTX nanoparticle platform to deliver therapeutic RNA to tumor cells, targeting metastatic disease. TransCode is advancing RNA-based therapies designed to address mechanisms that drive cancer progression and metastasis.